Current Report Filing (8-k)
January 11 2018 - 2:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): January 5,
2018
AMERICAN BIO MEDICA CORPORATION
(Exact
name of registrant as specified in its charter)
New
York
|
0-28666
|
14-1702188
|
(State
or other jurisdiction of incorporation)
|
(Commission File
Number)
|
(IRS
Employer Identification Number)
|
122 Smith Road, Kinderhook,
NY
12106
(Address of
principal executive offices)
(Zip Code)
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2.
below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
ITEM
5.02
Departure
of Directors or Principal Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
Upon
recommendation of American Bio Medica Corporation’s (the
“Company”) Nominating Committee of the Board of
Directors, on December 21, 2017 the Board of Directors approved the
appointment of Peter K. Jerome to fill a board seat vacancy created
by the resignation of Richard P. Koskey on April 6, 2017. Mr.
Jerome was also approved to be appointed to the Audit Committee of
the Company’s Board of Directors as its Chairman and, as the
Company’s audit committee financial expert. Mr. Jerome
accepted the nomination on January 5, 2018.
Since
February 2016, Mr. Jerome has been the Senior Director, Finance of
Taconic Biosciences, Inc., a company that develops and produces
animal research models for pharmaceutical and biotechnology
companies worldwide. Prior to his position with Taconic
Biosciences, Inc., Mr. Jerome served as the Chief Financial Officer
for CMP Pharma, Inc., a niche pharmaceutical company and Chief
Financial Officer for Tyratech, Inc., a life science company. Mr.
Jerome received his B.S in accounting and computer information
systems from Manhattan College and has been a certified public
accountant since 2004.
There
are no material arrangements, including compensation arrangements,
between Mr. Jerome and the Company other than customary
compensation to board members.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMERICAN BIO MEDICA
CORPORATION (Registrant)
|
|
|
|
|
|
Dated: January 11,
2018
|
By:
|
/s/
Melissa A.
Waterhouse
|
|
|
|
Melissa
A. Waterhouse
|
|
|
|
Chief
Executive Officer (Principal Executive Officer)
Principal Financial
Officer
|
|
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Aug 2024 to Sep 2024
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Sep 2023 to Sep 2024